Clinical trials
Phase 1 Lymphoma, B-Cell trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 7 |
| 2019 | 17 |
| 2020 | 5 |
| 2021 | 9 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 58 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 5 |
| Allife Medical Science and Technology Co., Ltd. | 4 |
| Henan Cancer Hospital | 4 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Peking University | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| Yan'an Affiliated Hospital of Kunming Medical University | 2 |
| iCell Gene Therapeutics | 2 |
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 1 |
| Ascentage Pharma Group Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, B-Cell | 58 |
| Recurrence | 15 |
| Burkitt Lymphoma | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Leukemia, B-Cell | 6 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Lymphoma | 4 |
| Leukemia | 3 |
| Lymphoma, Follicular | 3 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.